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LETTERS TO THE EDITOR	
Digoxin Withdrawal in Patients With
Head Failure
The report by Uretsky et al
. (t) is the second of two recent
withdrawal studies
(i,2)
that claim to show some advantage from the
use
of digoxin in the treatment of patients
with heart failure . The two
studies add to the large number of earlier studies that have used the
withdrawal design (3) .
The authors are parsimonious in enumerating
the limitations of their study .
A
withdrawal study addresses
the question whether stopping
the use of a drug brings about a change in the clinical condition of
the patient, not whether the drug should
have been prescribed in the
first place, Patients are selected
from those known to tolerate the
drug
. Such a subset of patients with heart failure may have unique
characteristics.
The major clinical question is not whether digoxin has a positive
isotropic effect or brings about clinical
benefit to selected patients
with heart failure but whether
the addition of digoxin to optimal
treatment with a diuretic agent and angiotensin-converting enzyme
inhibitor confers any
additional advantage to the patient . If a
withdrawal study is undertaken
to test this hypothesis, then on
withdrawal of the drug those patients randomized to placebo should
have their therapy manipulated either by an increase in the diuretic
agent, the addition of a
combination of diuretic agents or an
alteration in the dose of the angiotensin-converting enzyme inhibi-
tor. The two recent studies are at best tests
of the efficacy of digoxin
(not in dispute under particular circumstances) but are decidedly not
a fair test of a therapeutic strategy .
The most serious criticism of withdrawal
studies is that interpre-
tation of the results is ambiguous .
If, as was observed in this study,
there is deterioration in the placebo group on withdrawal of the
investi tional drug, a possible conclusion would be that the drug
has conferred benefit . An alternative conclusion is that the drug was
sufficiently efficacious to conceal any clinical deterioration while the
drug was being administered but at the same time caused harm .
Isotropic drugs can hasten cell death in the presence of myocardial
ischemia or in metabolically challenged myocytes . Under such
circumstances, cessation of the drug will be followed by deteriora-
tion of the patient. The deterioration is a measure of the harm
caused by the drug . Thus, the same outcome
can be used to argue
for efficacy or harm . Withdrawal studies are quite correctly not used
to investigate new drugs in heart failure .
The debate on the ~ linical use of digoxin will continue for many
years. The key issue is whether
a potentially harmful drug adds
benefit to established conventional treatment and whether there are
subgroups of patients in whom there is a particular benefit or harm
.
The outcome of the current mortality
study conducted by the
National Institu es of Health may provide
more convincing evidence
for the use of digoxin, namely, to influence long-term mortality
rather than to ameliorate symptoms.
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Reply
Dr. Paole-Wilson has several concerns about the recently published
placebo-controlled digoxin trial (PROVED) (1). He questions the
scientific validity of a drug withdrawal design . Such a design was
necessitated by the nearly universal use of digoxin in the treatment
of heart failure in this country at the time that this study was
promulgated
. A limitation of this design, not mentioned by Dr .
Poole-Wilson, is more on the ethical level, that is, clinical worsening
in the group withdrawn from the active therapeutic agent . To
safeguard against "excessive" deterioration,
the protocol mandated
that study coordinators contact patients weekly by telephone to
assess clinical status . If in a controlled trial, all measured baseline
variables are not significantly different and the only difference
during active phase is drug (digoxin) withdrawal in one patient
group, then it is completely reasonable to conclude that a worsening
in the placebo-treated group is due to withdrawal of the active agent
(digoxin) 6c ., digoxin has clinical efficacy)
. On the basis of the
PROVED study . it
is an extrapolation
to conclude that beginning
digoxin therapy in patients with clinical heart failure improves their
clinical status
. but it is more a "small step" than a "leap" of faith .
Dr
. Poole-Wilson questions whether digoxin can improve clinical
status in patients taking an angiotensin-converting enzyme inhibitor
and diuretic agents . The RADIANCE trial, with identical method-
ology to PROVED, except that patients were taking an angiotensin-
converting enzyme inhibitor by design, showed nearly identical
results to the PROVED trial (2) .
Whether, in addition to an angiotensin-converting enzyme inhib-
itor, using digoxin or increasing the dose of a diuretic agent, as Dr .
Poole-Wilson suggests, is a more appropriate strategy in the treat-
ment of decompensated heart failure, we would leave to the treating
physician, We would remind Dr. Poole-Wilson of the negative
effects of diuretic agents, particularly hypokalemia and hypontag-
nesemia, which may increase the propensity to fatal arrhythmias
and also further activation of potentially harmful neurohormonal
axes
.
Dr. Poole-Wilson states that the PROVED trial cannot answer
whether digoxin "should have been prescribed in the first place ."
We would remind Dr. Poole-Wilson that digoxin was prescribed in
all patients for at least one episode of clinical heart failure secondary
to systolic dysfunction . We would venture to say that tolerance to
oral digoxinn is high and that this
"subset" probably represents the
vast majority of patients with systolic dysfunction and clinical
congestive heart failure .
Finally, Dr
. Poole-Wilson muddies the issue of clinical efficacy of a
drug and its effect on survival. The PROVED (and RADIANCE) trials
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